Gujarat Themis Biosyn to Buy 13 Sanofi Brands in 2026

Deal announced through stock exchange disclosure

Gujarat Themis Biosyn Limited (GTBL) informed stock exchanges on 23 April 2026 that it has signed an asset purchase agreement with Sanofi. Sanofi is described as the French holding company of the Sanofi group, headquartered in Paris. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The agreement covers the acquisition of a portfolio of anti-tuberculosis (TB) and anti-infective brands. It also includes associated trademark rights linked to those brands.

What GTBL is buying from Sanofi

GTBL will acquire 13 established branded generic products from Sanofi. The brands have a presence across more than 55 countries in Europe, the Middle East and Africa. Along with the brands, the transaction includes marketing authorizations, regulatory dossiers, inventory and associated commercial rights. The company positioned the purchase as a way to strengthen its global generic pharmaceuticals platform, especially in anti-infectives. The portfolio is intended to add finished dosage formulations exposure to GTBL’s existing capabilities.

Consideration, funding plan, and expected closing

The consideration for the transaction is EUR 158 million, payable in cash at closing. GTBL said it expects to fund the payout through an “optimal mix” of debt and equity. The company has indicated an expected closing by the end of Q3 FY27, specified as 31 December 2026. The timeline is subject to customary closing conditions. GTBL also disclosed that the acquisition is not a related party transaction.

Revenue profile of the acquired portfolio

The acquired portfolio reported net sales of approximately EUR 62 million for the year ended 2025. GTBL also disclosed the revenues of the 13 products over the last three fiscal years. Revenues were EUR 66 million in FY23 and EUR 67 million in FY24, before declining to EUR 62 million in FY25. These figures provide a three-year view of the portfolio’s scale and recent trend.

Why GTBL says the assets fit its strategy

GTBL described the purchase as a step to expand its presence in the anti-infective segment. The company said it would gain immediate access to regulated and semi-regulated markets through an existing international footprint. GTBL also highlighted a forward integration opportunity, where it can support acquired finished dosage formulations using its existing capabilities in fermentation-based intermediates and APIs. The disclosure noted that the portfolio operates at healthy gross margins. It also flagged potential margin improvement through backward integration and operational efficiencies.

Asset-light structure and what is not included

The transaction is structured as an asset purchase rather than an acquisition of an entity. GTBL stated that it is not acquiring any legal entity, manufacturing facilities or employees. In GTBL’s framing, this makes the expansion capital-efficient and asset-light. The included assets are commercial and regulatory in nature, such as brands and dossiers, which are critical for continued sales in multiple jurisdictions. The disclosure emphasised that the structure avoids taking on operational infrastructure through the deal itself.

Regulatory approvals and conditions to closing

GTBL said the acquisition is subject to antitrust and foreign direct investment approvals in applicable jurisdictions, along with other clearances. This means the deal timetable is linked to regulatory processes across markets where the brands are commercialised. The company’s target completion date, end-December 2026, reflects a closing window that accommodates these approvals. Until these conditions are met and closing occurs, the cash consideration is not payable. GTBL did not disclose any other financial terms in the announcement.

EPS and integration commentary provided by the company

GTBL stated that the transaction is expected to be EPS accretive. The company linked this expectation to profitable branded generics sales, vertical integration and improved operating leverage. It also pointed to potential for further improvement through backward integration and operational efficiencies, given its capabilities in fermentation-based intermediates and APIs. Importantly, the disclosure did not provide quantified synergy numbers or a post-deal margin target. The stated logic rests on combining established branded generics with GTBL’s existing manufacturing strengths.

GTBL business background cited in the disclosure context

GTBL is described as an Indian pharmaceutical company focused on manufacturing active pharmaceutical ingredients (APIs) and fermentation-based products. The provided company background notes that it was incorporated in 1981 and commenced production in August 1985. It also states that GTBL was India’s first company to start commercial production of the anti-tuberculosis drug Rifampicin. The background material further describes GTBL’s API portfolio including Rifamycin S and Rifamycin O, and notes a cGMP-approved manufacturing plant located at Vapi, Valsad, Gujarat. In financial context included alongside the deal narrative, the company’s gross margin for the quarter ending 30 September 2025 was stated as 66.66%, with a net profit margin of 33.68% for the same quarter.

Shareholder voting disclosure included with the filing

Alongside the transaction narrative, GTBL also disclosed voting details for resolutions. Out of total outstanding shares of 108,965,265, votes polled for the first resolution were 79,333,821, representing 72.8065% of outstanding shares. For the second resolution, 2,652,014 votes were polled, representing 2.4338% of outstanding shares. The company stated that voting results and the scrutinizer’s report were made available on its website at www.gtbl.in. The disclosure framed this as part of transparency and regulatory compliance.

What investors can monitor next

The key near-term milestones are regulatory and antitrust clearances and the eventual closing targeted for 31 December 2026. Investors will also watch how GTBL finalises its funding mix of debt and equity for the EUR 158 million cash payment at closing. Another area to track is how GTBL operationalises the forward integration thesis, given the portfolio’s finished dosage formulations and GTBL’s API and fermentation capabilities. Any further disclosures under SEBI regulations on approvals, funding, and closing conditions will shape the next updates on the transaction.